Apigenin and breast cancers: From chemistry to medicine

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 6, 2015, Pages 728-735

  Nabavi, Seyed Mohammad ^a   Habtemariam, Solomon ^b   Daglia, Maria ^c   Nabavi, Seyed Fazel ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF GREENWICH   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Apigenin; Apoptosis; Aromatase activity; Breast cancer

Indexed keywords

APIGENIN; CASPASE 3; CASPASE 8; CYCLOOXYGENASE 2; CYTOCHROME C; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT MEDICINAL PRODUCT; PROTEIN BAX; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FLAVONOID; PLANT EXTRACT;

ABTS RADICAL SCAVENGING ASSAY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; DPPH RADICAL SCAVENGING ASSAY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FREE RADICAL SCAVENGING ASSAY; HUMAN; HYDROXYL RADICAL SCAVENGING ASSAY; LIPOPHILICITY; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; SUPEROXIDE ANION RADICAL SCAVENGING ASSAY; UPREGULATION; ANIMAL; BIOAVAILABILITY; BREAST NEOPLASMS; FEMALE;

ANIMALS; ANTINEOPLASTIC AGENTS; APIGENIN; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; FEMALE; FLAVONOIDS; HUMANS; PHYTOCHEMICALS; PLANT EXTRACTS;

EID: 84934783316     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150304120643     Document Type: Article

References (115)

1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2014.
2. DeSantis, C.; Ma, J.; Bryan, L.; Jemal, A. Breast cancer statistics, 2013. CA Cancer. J. Clin., 2014, 64(1), 52-62.
3. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer, 2013, 49(6), 1374-1403.
4. Ottini, L. Male breast cancer: A rare disease that might uncover underlying pathways of breast cancer. Nat. Rev. Cancer, 2014, 14(10), 643.
5. Li, C.; Uribe, D.; Daling, J. Clinical characteristics of different histologic types of breast cancer. Br. J. cancer, 2005, 93(9), 1046-1052.
6. Buerger, H.; Simon, R.; Schafer, K.; Diallo, R.; Littmann, R.; Poremba, C.; Van Diest, P.; Dockhorn-Dworniczak, B.; Bocker, W. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol. Pathol., 2000, 53(3), 118-121.
7. Li, C. I.; Malone, K. E.; Saltzman, B. S.; Daling, J. R. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer, 2006, 106(10), 2104-2112.
8. DeSantis, C.; Siegel, R.; Bandi, P.; Jemal, A. Breast cancer statistics, 2011. CA Cancer. J. Clin., 2011, 61(6), 408-418.
9. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18(3), 581-592.
10. Smigal, C.; Jemal, A.; Ward, E.; Cokkinides, V.; Smith, R.; Howe, H. L.; Thun, M. Trends in breast cancer by race and ethnicity: Update 2006. CA Cancer. J. Clin., 2006, 56(3), 168-183.
11. Altekruse, S.; Kosary, C.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H. SEER cancer statistics review, 1975-2007. Bethesda, MD: National Cancer Institute, 2010, 7.
12. Majed, B.; Moreau, T.; Senouci, K.; Salmon, R. J.; Fourquet, A.; Asselain, B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res. Treat., 2008, 111(2), 329-342.
13. Yancik, R.; Wesley, M. N.; Ries, L. A.; Havlik, R. J.; Edwards, B. K.; Yates, J. W. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 2001, 285(7), 885-892.
14. Narod, S. A. Hormone replacement therapy and the risk of breast cancer. Nat. Rev. Clin. Oncol., 2011, 8(11), 669-676.
15. Chen, W. Y.; Rosner, B.; Hankinson, S. E.; Colditz, G. A.; Willett, W. C. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA, 2011, 306(17), 1884-1890.
16. Fagundes, C. P.; Lindgren, M. E.; Shapiro, C. L.; Kiecolt-Glaser, J. K. Child maltreatment and breast cancer survivors: Social support makes a difference for quality of life, fatigue and cancer stress. Eur. J. Cancer, 2012, 48(5), 728-736.
17. Yu, K. D.; Shao, Z. M. Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer. Nat. Rev. Cancer, 2012, 12(5), 372-373.
18. Nabavi, S. F.; Daglia, M.; Moghaddam, A. H.; Habtemariam, S.; Nabavi, S. M. Curcumin and liver disease: From chemistry to medicine. Compr. Rev. Food Sci. Food Saf., 2014, 13(1), 62-77.
19. Lee, K. W.; Bode, A. M.; Dong, Z. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer, 2011, 11(3), 211-218.
20. Shu, L.; Cheung, K. L.; Khor, T. O.; Chen, C.; Kong, A. N. Phytochemicals: Cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis. Rev., 2010, 29(3), 483-502.
21. Goodman, M.; Bostick, R. M.; Kucuk, O.; Jones, D. P. Clinical trials of antioxidants as cancer prevention agents: Past, present, and future. Free Radic. Biol. Med., 2011, 51(5), 1068-1084.
22. Bishayee, A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev. res., 2009, 2(5), 409-418.
23. Curti, V.; Capelli, E.; Boschi, F.; Nabavi, S. F.; Bongiorno, A. I.; Habtemariam, S.; Nabavi, S. M.; Daglia, M. Modulation of human miR+17-3p expression by methyl 3+O-methyl gallate as explanation of its in vivo protective activities. Mol. Nutr. Food Res., 2014, 58(9), 1776-1784.
24. Shu, X. O.; Zheng, Y.; Cai, H.; Gu, K.; Chen, Z.; Zheng, W.; Lu, W. Soy food intake and breast cancer survival. JAMA, 2009, 302(22), 2437-2443.
25. Rock, C. L.; Demark-Wahnefried, W. Nutrition and survival after the diagnosis of breast cancer: A review of the evidence. J. Clin. Oncol., 2002, 20(15), 3302-3316.
26. Thomson, C. A.; Flatt, S. W.; Rock, C. L.; Ritenbaugh, C.; Newman, V.; Pierce, J. P. Increased fruit, vegetable and fiber intake and lower fat intake reported among women previously treated for invasive breast cancer. J. Am. Diet. Assoc., 2002, 102(6), 801-808.
27. Nabavi, S. M.; Nabavi, S. F.; Eslami, S.; Moghaddam, A. H. In vivo protective effects of quercetin against sodium fluoride-induced oxidative stress in the hepatic tissue. Food Chem., 2012, 132(2), 931-935.
28. Nabavi, S. F.; Nabavi, S. M.; Mirzaei, M.; Moghaddam, A. H. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat's heart. Food funct, 2012, 3(4), 437-441.
29. Xiao, Z. P.; Peng, Z. Y.; Peng, M. J.; Yan, W. B.; Ouyang, Y. Z.; Zhu, H. L. Flavonoids health benefits and their molecular mechanism. Mini Rev. Med. Chem., 2011, 11(2), 169-177.
30. Haddad, A. Q.; Fleshner, N.; Nelson, C.; Saour, B.; Musquera, M.; Venkateswaran, V.; Klotz, L. Antiproliferative mechanisms of the flavonoids 2, 2′-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr. Cancer, 2010, 62(5), 668-681.
31. Nabavi, S. F.; Nabavi, S. M.; Ebrahimzadeh, M. A.; Eslami, B.; Jafari, N. In Vitro Antioxidant and antihemolytic activities of hydroalcoholic extracts of Allium scabriscapum Boiss Ky. aerial parts and bulbs. Int. J. Food Prop., 2013, 16(4), 713-722.
32. Nabavi, S. F.; Nabavi, S. M.; N Setzer, W.; Nabavi, S. A.; Nabavi, S. A.; Ebrahimzadeh, M. A. Antioxidant and antihemolytic activity of lipid-soluble bioactive substances in avocado fruits. Fruits, 2013, 68(3), 185-193.
33. Alinezhad, H.; Azimi, R.; Zare, M.; Ebrahimzadeh, M. A.; Eslami, S.; Nabavi, S. F.; Nabavi, S. M. Antioxidant and antihemolytic activities of ethanolic extract of flowers, leaves, and stems of Hyssopus officinalis L. Var. angustifolius. Int. J. Food Prop., 2013, 16(5), 1169-1178.
34. Del Rio, D.; Costa, L.; Lean, M.; Crozier, A. Polyphenols and health: What compounds are involved? Nutr. Metab. Cardiovasc. Dis., 2010, 20(1), 1-6.
35. Daglia, M.; Di Lorenzo, A.; F Nabavi, S.; S Talas, Z.; M Nabavi, S. Polyphenols: Well beyond the antioxidant capacity: Gallic acid and related compounds as neuroprotective agents: You are what you eat! Curr. Pharm. Biotechnol., 2014, 15(4), 362-372.
36. Nabavi, S. F.; Russo, G. L.; Daglia, M.; Nabavi, S. M. Role of quercetin as an alternative for obesity treatment: You are what you eat!. Food Chem., 2015, 179, 305-310.
37. Nabavi, S. F.; Nabavi, S. M.; Habtemariam, S.; Moghaddam, A. H.; Sureda, A.; Jafari, M.; Latifi, A. M. Hepatoprotective effect of gallic acid isolated from Peltiphyllum peltatum against sodium fluorideinduced oxidative stress. Ind. Crops Prod., 2013, 44, 50-55.
38. Nabavi, S. F.; Nabavi, S. M.; Moghaddam, A. H.; Naqinezhad, A.; Bigdellou, R.; Mohammadzadeh, S. Protective effects of Allium paradoxum against gentamicin-induced nephrotoxicity in mice. Food funct., 2012, 3(1), 28-29.
39. Le Marchand, L. Cancer preventive effects of flavonoids-a review. Biomed. Pharmacother., 2002, 56(6), 296-301.
40. Hui, C.; Yujie, F.; Lijia, Y.; Long, Y.; Hongxia, X.; Yong, Z.; Jundong, Z.; Qianyong, Z.; Mantian, M. MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3, 6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res., 2012, 14(3), R80.
41. Jeong, H. J.; Shin, Y. G.; Kim, I. H.; Pezzuto, J. M. Inhibition of aromatase activity by flavonoids. Arch. Pharm. Res., 1999, 22(3), 309-312.
42. Das, A.; Banik, N. L.; Ray, S. K. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer, 2010, 116(1), 164-176.
43. Fotsis, T.; Pepper, M. S.; Aktas, E.; Breit, S.; Rasku, S.; Adlercreutz, H.; Wahala, K.; Montesano, R.; Schweigerer, L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res., 1997, 57(14), 2916-2921.
44. Choi, J. A.; Kim, J. Y.; Lee, J. Y.; Kang, C. M.; Kwon, H. J.; Yoo, Y.-D.; Kim, T. W.; Lee, Y. S.; Lee, S. J. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol., 2001, 19(4), 837-844.
45. Miean, K. H.; Mohamed, S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem., 2001, 49(6), 3106-3112.
46. Long, X.; Fan, M.; Bigsby, R. M.; Nephew, K. P. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms. Mol. Cancer Ther., 2008, 7(7), 2096-2108.
47. Way, T. D.; Kao, M. C.; Lin, J. K. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. Febs lett., 2005, 579(1), 145-152.
48. Habtemariam, S. Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-α in L-929 tumor cells. J. Nat. Prod., 1997, 60(8), 775-778.
49. Habtemariam, S. Natural inhibitors of tumour necrosis factor-alpha production, secretion and function. Planta Med., 2000, 66(4), 303-313.
50. Habtemariam, S. Alpha-glucosidase inhibitory activity of kaempferol-3-O-rutinoside. Nat. Prod. Commun., 2011, 6(2), 201-203.
51. Habtemariam, S. K.; Varghese, G. The antidiabetic therapeutic potential of dietary polyphenols. Curr. Pharm. Biotechnol., 2014, 15(4), 391-400.
52. Fang, J.; Xia, C.; Cao, Z.; Zheng, J. Z.; Reed, E.; Jiang, B. H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J., 2005, 19(3), 342-353.
53. Gupta, S.; Afaq, F.; Mukhtar, H. Involvement of nuclear factorkappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene, 2002, 21(23), 3727-3738.
54. Peterson, J.; Dwyer, J. Flavonoids: Dietary occurrence and biochemical activity. Nutr. Res., 1998, 18(12), 1995-2018.
55. Bevilacqua, L.; Buiarelli, F.; Coccioli, F.; Jasionowska, R. Identification of Compounds in Wine by HPLC-Tandem Mass Spectrometry. Ann. Chim., 2004, 94(9-10), 679-690.
56. Gerhauser, C. Beer constituents as potential cancer chemopreventive agents. Eur. J. Cancer, 2005, 41(13), 1941-1954.
57. Švehlíkova, V.; Bennett, R. N.; Mellon, F. A.; Needs, P. W.; Piacente, S.; Kroon, P. A.; Bao, Y. Isolation, identification and stability of acylated derivatives of apigenin 7-O-glucoside from chamomile (Chamomilla recutita[L.] Rauschert). Phytochemistry, 2004, 65(16), 2323-2332.
58. Mckay, D. L.; Blumberg, J. B. A review of the bioactivity and potential health benefits of chamomile tea. Phytother Res., 2006, 20(7), 519-530.
59. Chen, H.; Mrazek, A. A.; Wang, X.; Ding, C.; Ding, Y.; Porro, L. J.; Liu, H.; Chao, C.; Hellmich, M. R.; Zhou, J. Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fibrosis in vivo. Bioorg. Med. Chem., 2014, 22(13), 3393-3404.
60. Hutchins, W.; Wheeler, T. 17. Chalkones: A new synthesis of chrysin, apigenin, and luteolin. J. Chem. Soc., 1939, 91-94.
61. Liu, R.; Zhang, H.; Yuan, M.; Zhou, J.; Tu, Q.; Liu, J.-J.; Wang, J. Synthesis and biological evaluation of apigenin derivatives as antibacterial and antiproliferative agents. Molecules, 2013, 18(9), 11496-11511.
62. Wang, Q. Q.; Cheng, N.; Yi, W. B.; Peng, S. M.; Zou, X. Q. Synthesis, nitric oxide release and α-glucosidase inhibition of nitric oxide donating apigenin and chrysin derivatives. Bioorg. Med. Chem., 2014, 22(5), 1515-1521.
63. Cardenas, M.; Marder, M.; Blank, V. C.; Roguin, L. P. Antitumor activity of some natural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Bioorg. Med. Chem., 2006, 14(9), 2966-2971.
64. Rosenberg, R. S.; Grass, L.; Jenkins, D. J.; Kendall, C. W.; Diamandis, E. P. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. Biochem. Biophys. Res. Commun., 1998, 248(3), 935-939.
65. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12(3), 413-420.
66. Zhang, J.; Liu, D.; Huang, Y.; Gao, Y.; Qian, S. Biopharmaceutics classification and intestinal absorption study of apigenin. Int. J. Pharm., 2012, 436(1), 311-317.
67. Meyer, H.; Bolarinwa, A.; Wolfram, G.; Linseisen, J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab., 2006, 50(3), 167-172.
68. Arsić, I.; Tadić, V.; Vlaović, D.; Homšek, I.; Vesić, S.; Isailović, G.; Vuleta, G. Preparation of novel apigenin-enriched, liposomal and non-liposomal, antiinflammatory topical formulations as substitutes for corticosteroid therapy. Phytother. Res., 2011, 25(2), 228-233.
69. Al Shaal, L.; Muller, R.; Shegokar, R. smartCrystal combination technology-scale up from lab to pilot scale and long term stability. Die. Pharmazie., 2010, 65(12), 877-884.
70. Das, S.; Das, J.; Samadder, A.; Paul, A.; Khuda-Bukhsh, A. R. Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. Toxicol. lett., 2013, 223(2), 124-138.
71. Chen, R.; Hollborn, M.; Grosche, A.; Reichenbach, A.; Wiedemann, P.; Bringmann, A.; Kohen, L. Effects of the vegetable polyphenols epigallocatechin-3-gallate, luteolin, apigenin, myricetin, quercetin, and cyanidin in primary cultures of human retinal pigment epithelial cells. Mol. Vis., 2014, 3(20), 242-258.
72. Higdon, J. V.; Delage, B.; Williams, D. E.; Dashwood, R. H. Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharm. Res., 2007, 55(3), 224-236.
73. Gonzalez, C. A.; Pera, G.; Agudo, A.; Bueno-de-Mesquita, H. B.; Ceroti, M.; Boeing, H.; Schulz, M.; Del Giudice, G.; Plebani, M.; Carneiro, F. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int. J. Cancer, 2006, 118(10), 2559-2566.
74. Seeram, N. P.; Adams, L. S.; Hardy, M. L.; Heber, D. Total cranberry extract versus its phytochemical constituents: Antiproliferative and synergistic effects against human tumor cell lines. J. Agric. Food Chem., 2004, 52(9), 2512-2517.
75. Neto, C. C. Cranberry and its phytochemicals: A review of in vitro anticancer studies. J. Nutr., 2007, 137(1), 186S-193S.
76. Whitlock, N. C.; Baek, S. J. The anticancer effects of resveratrol: Modulation of transcription factors. Nutr. Cancer, 2012, 64(4), 493-502.
77. Romanova, D.; Vachalkova, A.; Cipak, L.; Ovesna, Z.; Rauko, P. Study of antioxidant effect of apigenin, luteolin and quercetin by DNA protective method. Neoplasma, 2000, 48(2), 104-107.
78. Lee, J. H.; Zhou, H. Y.; Cho, S. Y.; Kim, Y. S.; Lee, Y. S.; Jeong, C. S. Anti-inflammatory mechanisms of apigenin: Inhibition of cyclooxygenase-2 expression, adhesion of monocytes to human umbilical vein endothelial cells, and expression of cellular adhesion molecules. Arch. Pharm. Res., 2007, 30(10), 1318-1327.
79. Jeyabal, P. V. S.; Syed, M. B.; Venkataraman, M.; Sambandham, J. K.; Sakthisekaran, D. Apigenin inhibits oxidative stress-induced macromolecular damage in N-nitrosodiethylamine (NDEA)-induced hepatocellular carcinogenesis in Wistar albino rats. Mol. Carcinog., 2005, 44(1), 11-20.
80. Begum, N.; Prasad, N. R. Apigenin, a dietary antioxidant, modulates gamma radiation-induced oxidative damages in human peripheral blood lymphocytes. Biomed. Prev. Nutr., 2012, 2(1), 16-24.
81. Zhang, X.; Wang, G.; Gurley, E. C.; Zhou, H. Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PLoS One, 2014, 9(9), e107072.
82. Duarte, S.; Arango, D.; Parihar, A.; Hamel, P.; Yasmeen, R.; Doseff, A. I. Apigenin protects endothelial cells from lipopolysaccharide (LPS)-induced inflammation by decreasing caspase-3 activation and modulating mitochondrial function. Int. J. Mol. Sci., 2013, 14(9), 17664-17679.
83. Way, T. D.; Kao, M. C.; Lin, J. K. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neuoverexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 2004, 279(6), 4479-4489.
84. Lee, W. J.; Chen, W. K.; Wang, C. J.; Lin, W. L.; Tseng, T. H. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and β4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol., 2008, 226(2), 178-191.
85. Mak, P.; Leung, Y. K.; Tang, W. Y.; Harwood, C.; Ho, S. M. Apigenin suppresses cancer cell growth through ERβ. Neoplasia, 2006, 8(11), 896-904.
86. Mafuvadze, B.; Benakanakere, I.; Perez, F. R. L.; Besch-Williford, C.; Ellersieck, M. R.; Hyder, S. M. Apigenin prevents development of medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz (a) anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev. Res., 2011, 4(8), 1316-1324.
87. Seo, H. S.; Ku, J. M.; Choi, H. S.; Woo, J. K.; Jang, B. H.; Shin, Y. C.; Ko, S. G. Induction of caspase-dependent apoptosis by apigenin by inhibiting stat3 signaling in her2-overexpressing mda-mb-453 breast cancer cells. Anticancer Res., 2014, 34(6), 2869-2882.
88. Yin, F.; Giuliano, A. E.; Law, R. E.; Van Herle, A. J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res., 2000, 21(1A), 413-420.
89. Chen, D.; Landis-Piwowar, K. R.; Chen, M. S.; Dou, Q. P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res., 2007, 9(6), R80.
90. Seo, H. S.; Choi, H. S.; Kim, S. R.; Choi, Y. K.; Woo, S. M.; Shin, I.; Woo, J. K.; Park, S. Y.; Shin, Y. C.; Ko, S. K. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Mol. Cell. Biochem., 2012, 366(1-2), 319-334.
91. Yi Lau, G. T.; Leung, L. K. The dietary flavonoid apigenin blocks phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in breast cell lines. Food Chem. Toxicol., 2010, 48(10), 3022-3027.
92. Mafuvadze, B.; Benakanakere, I.; Hyder, S. M. Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause, 2010, 17(5), 1055-1063.
93. Cip1 and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J. Nutr. Biochem., 2009, 20(4), 285-290.
94. Liao, Y. F.; Rao, Y. K.; Tzeng, Y. M. Aqueous extract of Anisomeles indica and its purified compound exerts anti-metastatic activity through inhibition of NF-κB/AP-1-dependent MMP-9 activation in human breast cancer MCF-7 cells. Food Chem. Toxicol., 2012, 50(8), 2930-2936.
95. Lindenmeyer, F.; Li, H.; Menashi, S.; Soria, C.; Lu, H. Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr. cancer, 2001, 39(1), 139-147.
96. Jin, X.; Ren, C. Effect and mechanism of apigenin on VEGF expression in human breast cancer cells. Zhonghua. Zhong. Liu. Za. Zhi., 2007, 29(7), 495-499.
97. Beral, V.; Banks, E.; Reeves, G.; Bull, D. Breast cancer and hormone-replacement therapy: The million women study. Lancet, 2003, 362(9392), 1330-1331.
98. Hyder, S. M.; Chiappetta, C.; Stancel, G. M. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int. J. Cancer, 2001, 92(4), 469-473.
99. Choi, E. J.; Kim, G. H. 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol. Rep., 2009, 22(6), 1533-1537.
100. Mafuvadze, B.; Liang, Y.; Besch-Williford, C.; Zhang, X.; Hyder, S. M. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm. Cancer, 2012, 3(4), 160-171.
101. Seo, H. S.; DeNardo, D. G.; Jacquot, Y.; Laios, I.; Vidal, D. S.; Zambrana, C. R.; Leclercq, G.; Brown, P. H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat., 2006, 99(2), 121-134.
102. Mafuvadze, B.; Cook, M.; Xu, Z.; Besch-Williford, C. L.; Hyder, S. M. Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7, 12-dimethylbenz (a) anthracene-induced breast cancer model. Nutr. Cancer, 2013, 65(8), 1184-1191.
103. Yang, M. H.; Kim, J.; Khan, I. A.; Walker, L. A.; Khan, S. I. Nonsteroidal anti-inflammatory drug activated gene-1 (NAG-1) modulators from natural products as anti-cancer agents. Life Sci., 2014, 100(2), 75-84.
104. Li, F.; Ye, L.; Lin, S. M.; Leung, L. K. Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Mol. Cell. Endocrinol., 2011, 344(1), 51-58.
105. Simpson, E. R.; Mahendroo, M. S.; Means, G. D.; Kilgore, M. W.; Hinshelwood, M. M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C. R.; Michael, M. D. Aromatase cytochrome P450, The enzyme responsible for estrogen biosynthesis. Endocr. Rev., 1994, 15(3), 342-355.
106. Simpson, E. R.; Davis, S. R. Minireview: Aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology, 2001, 142(11), 4589-4594.
107. Brueggemeier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev., 2005, 26(3), 331-345.
108. Wood, A. J.; Smith, I. E.; Dowsett, M. Aromatase inhibitors in breast cancer. New Engl. J. Med., 2003, 348(24), 2431-2442.
109. Kellis, J. T.; Vickery, L. E. Inhibition of human estrogen synthetase (aromatase) by flavones. Science, 1984, 225(4666), 1032-1034.
110. Pelissero, C.; Lenczowski, M.; Chinzi, D.; Davail-Cuisset, B.; Sumpter, J.; Fostier, A. Effects of flavonoids on aromatase activity, an in vitro study. J. Steroid Biochem. Mol. Biol., 1996, 57(3), 215-223.
111. Kuhajda, F. P. Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition, 2000, 16(3), 202-208.
112. Kuhajda, F. P. Fatty acid synthase and cancer: New application of an old pathway. Cancer Res., 2006, 66(12), 5977-5980.
113. Pizer, E. S.; Wood, F. D.; Pasternack, G. R.; Kuhajda, F. P. Fatty acid synthase (FAS): A target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res., 1996, 56(4), 745-751.
114. R Pandey, P.; Liu, W.; Xing, F.; Fukuda, K.; Watabe, K. Anticancer drugs targeting fatty acid synthase (FAS). Rec. Pat. Anticancer Drug Discov., 2012, 7(2), 185-197.
115. Menendez, J. A.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Garcia-Villalba, R.; Carrasco-Pancorbo, A.; Fernandez-Gutierrez, A.; Segura-Carretero, A. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays. Int. J. Mol. Med., 2008, 22(4), 433-439.